Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.5. Antifungal |
Others observations: For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients. |
| Chile | Essential and Prioritized Medications | No observations |
| Cuba | 6.3 Antimicóticos | No observations |
| WHO Model List of Essential Medicines (2021) | 6.3. Antifungal medicines |
Others observations: For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients. |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.5. Antifungal |
Others observations: For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients. |
| WHO Model List of Essential Medicines (2021) | 6.3. Antifungal medicines |
Others observations: For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients. |
| List | Section | Observation |
|---|---|---|
| Peru | 6.3 Antifungals | No observations |